Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

Long-acting injectable antipsychotics (LAIs) were developed to make treatment easier, improve adherence, and/or signal the clinician when nonadherence occurs. Second-generation antipsychotic LAIs (SGA-LAIs) combine the advantages of SGA with a long-acting formulation. The purpose of this review is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Montemagni, Cristiana, Frieri, Tiziana, Rocca, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844443/
https://www.ncbi.nlm.nih.gov/pubmed/27143893
http://dx.doi.org/10.2147/NDT.S88632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844443/
https://www.ncbi.nlm.nih.gov/pubmed/27143893
http://dx.doi.org/10.2147/NDT.S88632

Ejemplares similares